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ABSTRACT 
Objective. To identify markers associated with the chondrogenic capacity (CC) of 
expanded human articular chondrocytes and to use these markers for sorting of more 
chondrogenic subpopulations. 
Methods. The CC of chondrocyte populations derived from different donors (n=21) or 
different clonal strains from the same cartilage biopsy (n=21) was defined based on the 
glycosaminoglycan (GAG) content of tissues generated using a pellet culture model. 
Selected cell populations were analysed by microarray and cytofluorimetry. In some 
experiments, cells were sorted using antibodies against molecules found to be associated 
with differential CC and again assessed in pellet cultures. 
Results. Significance analysis of microarrays indicated that chondrocytes with low CC 
expressed greater levels of insulin-like growth factor-1 and of catabolic genes (e.g., 
metalloproteinase-2, aggrecanase-2), while chondrocytes with high CC expressed greater 
levels of genes involved in cell-cell or cell-matrix interactions (e.g., CD49c, CD49f). 
Cytofluorimetry analysis showed that CD44, CD151 and CD49c were expressed at 
significantly greater levels in chondrocytes with higher CC. Cytofluorimetrical analysis 
of clonal chondrocyte strains indicated that CD44 and CD151 can also identify more 
chondrogenic clones. Chondrocytes sorted for brighter CD49c or CD44 signal expression 
produced tissues with higher GAG/DNA (up to 1.4-fold) and collagen type II mRNA (up 
to 3.4-fold) than unsorted cells.  
Conclusion. We identified markers enabling to characterize the capacity of monolayer 
expanded chondrocytes to form in vitro cartilaginous tissue and to enrich for 
subpopulations with higher CC. These markers might be used as a mean to predict and 
possibly improve the outcome of cell-based cartilage repair techniques. 
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Cellular therapy and tissue engineering are promising strategies for the repair of missing, 
degenerated or diseased tissues in the human body. In the past few decades, the search 
for innovative cell-based repair strategies has been particularly intense for the treatment 
of cartilage lesions, due to the large number of clinical cases, the limited inherent 
capacity of articular cartilage to heal, and the limitations of current treatment methods 
(1,2). Current cell-based strategies to induce cartilage repair include autologous 
chondrocyte implantation (3) and a more recent alternative movement towards 
prefabrication of cartilaginous implants (4-11). Both methods rely on the expansion of a 
limited population of chondrocytes derived from a small cartilage biopsy, intrinsically 
associated with cellular de-differentiation (12), and on the ability of the expanded cells to 
re-differentiate and generate cartilaginous tissue. However, the chondrogenic capacity 
(CC) of chondrocytes has been shown to be highly dependent on a wide variety of 
factors, including the biopsy site (13-15), the culture medium supplements (16,17), and 
the duration of expansion (18). Even using identical harvest and culture conditions, we 
previously demonstrated that human articular chondrocytes from different individuals 
display extreme variability in the in vitro CC; such variability is clearly age-related, but 
can be observed even among individuals within the same age range (19). Before cell-
based cartilage regeneration can be included as a standard method in the routine tool kit 
of medical application and widely accepted by healthcare systems, it will be necessary to 
identify means of predicting and possibly overcoming biological variations in different 
chondrocyte preparations. 
We recently established that clonal populations of human chondrocytes derived from the 
same biopsy also exhibit a large variability in the post-expansion re-differentiation 
capacity (20). This finding suggests that the identification of markers predictive of the 
cell CC could not only help identify the quality of expanded chondrocytes, but also allow 
enrichment of more chondrogenic cell subpopulations, to possibly improve the quality of 
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the generated tissues. However, markers to predict human chondrocyte CC are not yet 
available. Previous studies reported that a reduction of cartilage forming capacity upon 
extensive cell expansion is related to changes in the expression of a number of 
molecules, including a reduction in fibroblast growth factor receptor 3, bone 
morphogenic protein 2 and integrin alpha 3, accompanied by increased production of 
activin receptor-like kinase 1 (18,21). However, these studies were limited to comparison 
of the same primary cultures at different phases of expansion: thus, the expression of the 
candidate molecules was likely related to specific stages of chondrocyte differentiation, 
and might not capture inter- or intra-individual differences in cell CC. 
In this study, we first aimed at identifying markers differentially expressed by human 
articular chondrocyte populations displaying high or low CC, using a combination of 
microarray- and cytofluorimetry-based strategies. We then tested whether cell sorting 
using some of the identified markers could enhance the CC of expanded chondrocyte 
populations. The CC of cell preparations, derived from different donors or different 
clonal strains, was assessed in vitro using a well established pellet culture model. 
 
MATERIALS AND METHODS 
Cell isolation and culture. 
Human articular cartilage tissues were collected from 21 donors (age range: 40 to 60 
years; Mean±SE: 50.0±2.7; male=15, female=6) post mortem under local ethical 
guidelines (Bernische Ethik-Kommission). Only tissue from joints showing no sign of 
degenerative changes was used. Isolation and expansion of cells from the cartilage 
biopsies were carried out as previously described (19). In brief, each biopsy was digested 
in 0.15% type II collagenase and the remaining cells were expanded for two passages 
(average of 8-9 doublings) in DMEM with 10% fetal bovine serum, further 
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supplemented with 1ng/ml Transforming Growth Factor-1 (TGF1), 5ng/ml Fibroblast 
Growth Factor-2 and 10ng/ml Platelet Derived Growth Factor-BB (expansion medium). 
The expanded cells were then used for pellet cultures or cryopreserved for later 
microarray and cytofluorimetry analyses, as detailed below.  
Pellet culture, histology and biochemical analyses. 
The chondrogenic capacity (CC) of post-expanded chondrocytes was investigated in 
pellet cultures using a defined serum-free medium, as previously described (19). Briefly, 
chondrocytes were suspended in DMEM supplemented with ITS+1 (Sigma Chemical, St. 
Louis, MO), 0.1 mM ascorbic acid 2-phosphate, 1.25 mg/ml human serum albumin, 10-7 
M dexamethasone and 10 ng/mL TGF1. Aliquots of 5x105 cells/0.5 ml were 
centrifuged at 250 g for 5 minutes in 1.5 ml polypropylene conical tubes (Sarstedt, 
Nümbrecht, Germany) to form spherical pellets, which were placed onto a 3D orbital 
shaker (Bioblock Scientific, Frenkendorf, Switzerland) at 30 rpm. Pellets were cultured 
for 2 weeks, with medium changes twice per week, and subsequently processed for 
histological, immunohistochemical, biochemical or mRNA analysis as described below. 
Each analysis was performed independently in at least two entire pellets for each primary 
culture and expansion condition.  
For histology and immunohistochemistry, the pellets were fixed in 4% formalin, 
embedded in paraffin, cross-sectioned (5 µm thick) and stained with Safranin O for 
sulfated glycosaminoglycans (GAG) or processed for immunohistochemistry to visualize 
collagen type II (II-II6B3, Hybridoma Bank, University of Iowa, USA), as previously 
described (23). 
For biochemistry, the pellets were digested in Proteinase K (0.5 ml of 1 mg/ml protease 
K in 50 mM Tris with 1 mM EDTA, 1 mM iodoacetamide, and 10 µg/ml pepstatin-A for 
15 hours at 56°C) and then assessed for GAG content as described previously (24). The 
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DNA content was also measured in these samples by means of the CyQUANT Kit 
(Molecular Probes, Eugene, OR) using calf thymus DNA as a standard. GAG contents 
are reported as µg GAG per µg DNA. Each analysis was performed independently in at 
least two entire pellets for each primary culture and expansion condition.  
Clonal study. 
Cell cloning was performed by “limiting dilution” of cells from an additional cartilage 
biopsy from a 30 year old donor, as previously described (20). In brief, chondrocytes, 
freshly released enzymatically from the collected cartilage, were suspended at 5 cells/ml 
in expansion medium and 100 µl aliquots of the cell suspension were plated in 96 well 
plates. Cell populations arising from single cells were cultured till confluency and then 
passaged in 12 well plates. Upon r aching confluence, each clonal population was either 
cultured as pellet and processed histologically and biochemically, or cryopreserved for 
later surface marker analysis studies as detailed below. 
Definition of chondrocyte populations with low and high chondrogenic capacity 
(CC). 
The chondrogenic capacity (CC) of chondrocyte populations from different donors or 
from different clones was defined based on the distribution of the GAG/DNA contents of 
the resulting pellets. In particular, cells were considered as low CC or high CC if 
respectively in the lower 33% or the higher 33% of the distribution (see Table 1).  
GAG/DNA contents of pellets were previously shown to correlate with the mRNA 
expression and deposition of collagen type II (19) and with histological grading 
evaluation (22). 
Microarray analysis.  
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Cell populations from 9 donors were used for microarray analysis (5 cells populations 
with high CC and 4 cells populations with low CC). Since cells from 2 donors were 
assessed twice as technical replicate, in total 11 unique array data sets were generated 
(n=6 for high CC cells and n=5 for low CC cells). 
Total RNA from each cell population, expanded in monolayer for 2 passages, was 
isolated using the Qiagen RNeasy kit (Qiagen) in combination with DNase on column 
treatment (Qiagen). Total RNA (10Qg) was prepared for hybridization on the Human 
Genome U133A 2.0 Array with 14,500 genes with >22,000 probe sets (Affymetrix, Inc. 
Santa Clara, CA, USA) according to standard protocols (technical manual, version 
701021 Rev. 4; Affymetrix). 
Microarray Data analysis. 
Data were normalized using the GC-Robust Multi-Array Average (GC-RMA) (25), an 
algorithm provided by the Bioconductor project (www.bioconductor.org). Unsupervised 
hierarchical clustering was performed using the SpotfireTM decision site for functional 
genomics (www.spotfire.com). Significance analysis of microarrays (SAM) was 
preformed on two different subsets of the data, selected either with an average 
expression of at least 5-fold difference or with a variance of at least 0.025 (26). 
Significant differentially expressed genes are reported for high CC cells as fold change 
from low CC cells (positive = higher in high CC; negative = higher in low CC). The q-
value (%) was reported as a measure of the proportion of false positives incurred (called 
the false discovery rate) when the statistical test was called significant. 
Flow cytometric analysis and cell sorting. 
Surface marker expression on chondrocytes was quantified using cryopreserved cells 
according to a previously described protocol (27). In summary, cells were thawed, 
washed in 10ml of PBS and centrifuged at 400g for 5 minutes. After centrifugation the 
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cell concentration was adjusted to 5x106 cells per ml in PBS/BSA 1%. Three-color 
immunofluorescence analysis for different surface markers was performed by 
simultaneous labeling with mAb-FITC, mAb-PE, and 7-AAD. Each tube contained 105
cells. All incubation steps were performed at room temperature for 15 minutes in the 
dark and all washing steps were completed by centrifugation (5 minutes, 400g). Cells 
were kept at 4°C until they were analysed using a FACScan flow cytometer (Becton-
Dickinson). For each sample, a region for live cells (cells excluding 7-AAD) was 
defined, and at least 10,000 live chondrocytes were analyzed. Data were analyzed using 
FlowJo software (version 3.4, Tree Star Inc., San Carlos, CA). Non-specific staining was 
assessed using fluorochrome-, isotype- and species- matched immunoglobulins (isotype 
controls). The level of marker expression was calculated as the ratio between geometric 
mean fluorescence intensity (MFI) of sample cells and that of the isotype control. 
Cell sorting of chondrocytes was performed on a FACS Vantage flow cytometer 
(Becton-Dickinson). After culturing for two passages, cells were enzymatically detached, 
washed in PBS and centrifuged at 400g for 5 minutes. Cells were resuspended at 8 x 106
cells in PBS-BSA 1% and transferred to 12 x 75 mm Falcon tubes (Becton-Dickinson). 
Chondrocytes were then labelled with mAb against CD49c (4 individuals) or CD44 (1 
individual) and incubated for 15 minutes at room temperature in the dark.  Cells were 
then washed in 5ml of PBS-BSA 1% and centrifuged at 400g for 5 minutes. Pellets were 
finally resuspended in 2 ml of PBS-BSA 1% and the resulting cell suspension was 
passed through the cell sorter. Chondrocytes were collected without sorting (unsorted 
cells), or following sorting on the basis of the intensity of the labelling, using the mean 
fluorescence intensity as arbitrary threshold. Chondrocytes from the different 
populations (2-3x106) were then cultured in pellets as described above. Antibodies used 
for cytofluorimetry and cell sorting are listed in Table 2. 
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Statistical analysis. 
All values are reported as mean ± standard error of the mean. ANOVA was used to test 
whether differences existed in the levels of marker expression between the different CC 
groups (high and low). Post-hoc t-tests were used to identify significant relationships 
using the Holm’s step-down procedure to control the family-wise error rate. 
 
RESULTS 
Gene expression profiling of chondrocyte populations with high and low CC.  
Human articular chondrocyte populations with low CC or high CC (Table 1) were 
assessed via microarray to identify differentially expressed gene sets. Unsupervised 
hierarchical cluster analysis show d distinct separation of low CC and high CC cells 
(Figure 1a). Significance analysis of microarrays (SAM) revealed a number of 
differentially expressed genes (Figure 1b). Low CC was associated with an upregulation 
of extracellular matrix (ECM) catabolic enzymes, including metalloproteinase 2 
(MMP2), and ADAMTS-5 (aggrecanase 2) (Figure 1b), and with a higher expression of 
insulin like growth factor 1 (IGF-1) and of bone morphogenetic protein type IA receptor 
(BMPRIA). High CC cells expressed higher levels of the chondrogenic factor TGF-2, 
of several surface molecules, including chondroitin sulfate proteoglycan 4, syndecan 2 
and the integrin subunits alpha 3 (CD49c) and alpha 6 (CD49f), and of a number of 
intracellular proteins involved in the integrin signal transduction and cytoskeleton 
organization, such as actinin alpha 1, nebulette and embryonal Fyn-associated substrate 
(Figure 1b).  
Relation between chondrogenic capacity and surface marker expression: cells from 
different donors  
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Microarray data suggested that the expression of surface molecules could discriminate 
between chondrocyte preparations with low CC or high CC. Expanded chondrocytes 
were thus assessed by cytofluorimetry using antibodies against several clusters of 
differentiation (CD), typically used to characterize the phenotype of mesenchymal 
progenitor cells (28-30), and recently introduced to determine the stage of differentiation 
of human articular chondrocytes (27). For these experiments, we used cells with low CC 
from 6 donors (GAG/DNA of resulting pellets: 3.5±0.1 Qg/Qg) and cells with high CC 
from 5 donors (GAG/DNA of resulting pellets: 8.9±0.3 Qg/Qg). Representative Safranin 
O stained sections of pellets are shown in Figure 2a.  
Multiple comparison analysis indicated that cells with greater CC expressed higher levels 
of a number of surface molecules (Figure 2a; Table 3), all known to play a key role in 
mesenchymal condensations (31). These included: (i) integrin alpha 3 (CD49c), 
consistent with the microarray data; (ii) the hyaluronan receptor CD44; and (iii) the 
tetraspanin CD151.  
Relation between chondrogenic capacity and surface marker expression: cells from 
different clonal populations of the same biopsy 
In order to assess whether the same set of markers can identify more chondrogenic 
subpopulations within a heterogeneous primary culture, we performed cytofluorimetric 
analysis and chondrogenesis assays of different clonal populations derived from the same 
cartilage biopsy. 
Starting from one cartilage biopsy, we expanded 21 clonal chondrocyte populations, 
which were found to generate pellets of highly variable GAG contents (ranging 0.8 - 7.2 
Qg/Qg; Table 1). For these experiments we used 6 clones having low CC (GAG content 
of resulting pellets: 2.0±0.2 Qg/Qg) and 3 clones having high CC (GAG content of 
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resulting pellets: 6.6±0.3 Qg/Qg). Representative Safranin O stained sections of pellets 
are displayed in Figure 2b. 
The molecules CD44, CD90, CD151, CD49c, CD49e, CD49f and CD166 were all 
expressed at greater levels by high CC clones, although due to large variability in the 
intensity levels among different clones, statistical significance was established only for 
the first 3 (Figure 2b; Table 3). 
Sorting chondrocyte populations based on the expression level of surface molecules: 
enrichment of chondrogenic capacity 
The clonal analysis strongly suggested that the expression levels of specific surface 
molecules may identify the CC of chondrocyte subpopulations expanded from the same 
biopsy. Thus, we tested whether cell sorting using antibodies against integrin alpha 3 
(CD49c) and hyaluronan receptor (CD44) could enhance the CC of expanded 
chondrocyte populations. These molecules were selected based on their broad 
fluorescence signal profiles (see Figure 3a). Chondrocytes expressing these molecules at 
intensities greater than the mean fluorescence intensity (MFI) produced cartilage tissues 
containing higher amounts of type II collagen and GAG as compared to the unsorted 
chondrocyte populations (Figure 3c,d). Conversely, chondrocytes expressing CD49c or 
CD44 at levels lower than the MFI formed tissues with no detectable type II collagen 
and lower GAG content than the unsorted cells. Expression levels of type II collagen 
mRNA were consistent with the protein accumulation (Figure 3d). Interestingly, as 
compared to the unsorted chondrocyte populations, those with brighter CD49c signal 
showed a reduced inter-individual variability in CC, such that the coefficient of variation 
in the GAG content of pellets from the different donors (i.e., the standard deviation 
expressed as a percentage of the mean) decreased from 31.5% to 18.0% following cell 
sorting.  
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DISCUSSION 
In this study, we compared chondrocyte preparations from different donors or from 
different clonal strains, displaying low or high chondrogenic capacities (CC) in vitro. 
Using microarray and cytofluorimetry tools, we identified that cells with higher CC 
express lower levels of catabolic mediators and higher levels of surface molecules 
involved in early stages of cartilage development, including those involved in 
establishing cell-cell and cell-matrix interactions (e.g., the hyaluronan receptor CD44; 
the alpha 3 integrin subunit CD49c and the tetraspanin CD151). Finally, we verified that 
the CC of chondrocyte populations can be enhanced by sorting cells expressing higher 
levels of CD49c and CD44. 
Microarray analyses indicated that low CC chondrocyte populations expressed greater 
levels of catabolic mediators (i.e., matrix metalloproteinase 2 and aggrecanase 2), that 
would reduce the accumulation and retention of cartilage specific ECM in the reparative 
tissue. Low CC cells also upregulated the anabolic factor IGF1, possibly as an attempt to 
counteract the catabolic pathway and consistent with the characteristic concomitant 
activation of anabolic and catabolic pathways by chondrocytes in diseased joints (32). 
Another gene that was more expressed by low CC chondrocytes was BMPRIA, also 
known as activin receptor-like kinase (ALK)-3, a member of the TGF/BMP receptor 
type I. Interestingly, increased mRNA expression levels of ALK-1, another member of 
the same family, were previously shown to correlate with a reduced capacity of 
expanded chondrocyte to generate stable cartilage in vivo (18).  
High CC cells expressed higher levels of genes involved in the establishment of cell-
matrix interactions and in the transduction of integrin-mediated signals (i.e., actinin 
alpha 1, CD49c and CD49f). Since these processes are known to be important mediators 
of mesenchymal condensation, which is in turn required to initiate chondrogenesis (33-
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35), it is possible that high expression levels of these genes would increase the 
propensity of the cells to differentiate and produce cartilage ECM.  
Cytofluorimetrical analysis of monolayer expanded chondrocyte populations revealed 
that CD49c, CD151, CD44 were expressed at greater intensities in chondrocyte 
populations with high CC, in general agreement with the microarray results. 
Tetraspanins, such as CD151, are membrane proteins that bind to integrins and other 
proteins to generate functional complexes involved in cell-cell and cell-ECM interactions 
(36,37). CD151 has recently been shown to be part of a multimolecular complex 
consisting of integrin 31 and E-cadherin in epithelial cells, and to regulate cell-cell 
adhesion (38). The major receptor for hyaluronan, CD44, is highly expressed during 
mesenchymal cell condensation and plays an important role in chondrogenesis (39). The 
increased expression of CD44 in high CC is consistent with a recent study reporting 
upregulation of CD44 on human chondrocytes expanded on collagen type II coated 
dishes, which exhibit a superior capacity to generate cartilaginous tissues (40). 
Cytofluorimetrical analysis of clonal chondrocyte strains derived from a single cartilage 
biopsy indicated that CD44 and CD151 can also identify more chondrogenic clones 
within a heterogeneous primary culture. Markers characteristic of mesenchymal 
progenitor cells, i.e. CD90 and CD166 (29,41,42), were as well more expressed in high 
CC clones (although statistical significance was reached only for the former). This 
suggests that within a chondrocyte preparation, subpopulations with higher capacity to 
form cartilage might correspond to those with progenitor characteristics. Indeed, we 
previously demonstrated that some single colony-derived strains of expanded human 
chondrocytes display a multilineage differentiation potential (20), while other 
researchers have recently shown that different combinations of surface markers including 
CD90 and CD166 can be used to define sub-populations of chondrocytes with progenitor 
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features (43,44). In this context, it would be tempting to speculate that high CC clones 
reside in the surface layer of articular cartilage, which was postulated to contain a 
progenitor cell population (45). 
Chondrocytes expanded from different donors were then sorted for the expression level 
of CD49c and CD44. The superior quality of the cartilaginous tissues generated by 
chondrocytes with brighter CD49c or CD44 signal as compared to unsorted cells 
suggests that the low CC of certain chondrocyte preparations is due to contaminating 
populations (i.e., cells with low CD49c and/or CD44 signal). In this regard, it is possible 
that the threshold used for cell sorting, so far set at the mean fluorescence intensity, may 
need to be optimized to reach an efficient compromise between purity and quantity of the 
separated cells. Although the number of sorting experiments was relatively low, the 
observed reduced variability in CC by chondrocytes from different donors following 
sorting indicates the potential of the technique to achieve higher levels of standardization 
in cartilage tissue formation. It remains to be verified whether cell populations 
expressing high levels of CD49c coincide or not with those expressing high levels of 
CD44 and whether the same markers could be used to identify high CC chondrocytes 
immediately after isolation from the native cartilage.  
We are aware that the model used in the present study to characterize the CC of the cells 
(i.e., in vitro pellet culture), cannot directly predict the tissue-forming capacity of the 
cells when implanted in the joints of patients. On the other hand, studies using large 
animal models may not be helpful to validate our results, considering that human 
chondrocytes are known to be biologically different from those derived from other 
species. Ectopic implantation in nude mice might represent an alternative model to assess 
the cartilage forming capacity of human chondrocyte populations within an in vivo site 
(17,18). Although it does not mimic the complex biological and physical environment of 
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a load-bearing joint, the model would allow to investigate the intrinsic capacity of the 
human cells to form stable cartilage tissues, in a way that is not dependent upon TGF 
beta stimulation. Ultimately, however, our study prompts for the monitoring of the levels 
of expression of specific surface molecules in autologous chondrocyte populations, in 
parallel to their clinical use for cartilage repair. Establishing a correlation between the 
expression of such markers and clinical outcome could lead to the use of these molecules 
as a quality control to predict the result of autologous cell-based cartilage repair 
techniques and to possibly improve it by sorting specific cell subpopulations. This 
approach would exemplify how the combination of a diagnostic tool with the definition 
of a tailored therapy (i.e., the field recently called “theranostic”) could be extended from 
drug treatment to cell-based regenerative medicine.  
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Table 1. Glycosaminoglycans to DNA (GAG/DNA) content of donor and clonal cell 
populations screened in this study.  
 Donor # GAG/DNA Clone # GAG/DNA 
 1 2.2 1 0.8 
2 3.1 2 1.3 
low CC 3 3.2 3 1.4 
33% 4 3.3 4 1.5 
5 3.7 5 2.0 
6 3.8 6 2.2 
7 3.8 7 2.4 
8 4.5 8 2.5 
9 4.7 9 2.5 
middle CC 10 5.5 10 3.6 
 33% 11 6.0 11 3.9 
 12 6.2 12 4.0 
 13 6.5 13 4.1 
 14 7.2 14 4.5 
 15 8.1 15 4.6 
16 8.2 16 4.9 
high CC 17 8.9 17 5.7 
33% 18 9.2 18 6.3 
19 9.3 19 6.3 
20 9.5 20 6.4 
21 11.2 21 7.2 
Cell populations highlighted in grey were used in the array and/or FACS analysis as 
representative of low or high Chondrogenic Capacity (CC).  
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Table 2. Specification of antibodies presented in this study.  
Antigen recognized Isotype Cat. # / Flurochrome source 
CD44 (hyaluronan receptor) mIgG1 852.601.010 / FITC Diaclone 
CD49c (3 integrin chain) mIgG1 36615X / PE Pharmigen 
CD49e (5 integrin chain) mIgG2b MCA698 / PE  Serotec 
CD49f (6 integrin chain) mIgG2b MCA956 / PE  Serotec 
CD90 (Thy-1)  mIgG1 MCA90 / FITC Serotec 
CD151 (tetraspanin)  mIgG1 556057 / PE Pharmigen 
CD166 (ALCAM)  mIgG1 37615X / PE Pharmigen 
Table 3. Expression of surface markers in chondrocyte populations.  
 
Surface marker 
 
Donor-related 
populations 
(high CC/low CC) 
Clonal-related 
populations 
(high CC/low CC) 
CD44 (hyaluronan receptor) 1.5* 2.7* 
CD49c (integrin alpha 3) 2.7* 2.4 
CD49e (integrin alpha 5) 1.4 3.5 
CD49f (integrin alpha 6) 2.1 2.2 
CD90 (Thy-1) 1.2 1.6* 
CD151 (tetraspanin) 1.4* 4.2* 
CD166 (ALCAM) 1.5 3.1 
* P <0.05 from low chondrogenic capacity (CC) 
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FIGURE LEGENDS 
Figure 1. Gene expression analysis of low and high chondrogenic capacity (CC) 
cells. Unsupervised clustering dendrogram (a) has two major branches, indicating that 
high and low CC groups possess distinct and unique gene expression profiles. 
Significance Analysis of Microarrays (SAM) uncovered 229 genes differentially 
expressed, with a false discovery rate of 5.63% (Delta value of 1.14). The genes 
differentially expressed with statistical significance (b) are reported for high CC cells as 
fold change from low CC cells (positive = higher in high CC; negative = higher in low 
CC). Low CC cells display higher expression levels for insulin-like growth factor-I and 
various catabolic genes, while high CC cells have higher levels of expression of 
extracellular matrix, cytoskeleton and surface molecule genes that are known to be 
involved in early chondrogenesis. q-values (%) are a measure of false discovery rate. 
Figure 2. Chondrogenic capacity (CC) and surface marker expression of cells from 
different donors or clonal populations. 
Cells populations from different donors (a) and clones (b) were classified into low CC or 
high CC according to the glycosaminoglycan content of the generated tissues (see 
Methods and Table 1; representative Safranin-O stained histologies are presented) and 
characterized for the levels of expression of specific surface molecules. Overall, almost 
all of the surface molecules examined were expressed at higher levels in high CC cells 
derived from different donors or different clones, as compared to the low CC 
counterparts. A similar pattern of differences was observed using cells from different 
donors or from different clones. Values are reported as mean ± standard error of the 
mean. * = statistically significant difference between low and high CC cells.  
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Figure 3. Enhanced cartilage quality following cell sorting. (a) Typical expression 
profile of CD49c (integrin alpha 3 subunit) in cells with high and low chondrogenic 
capacity (CC) from different donors. CD44 (hyaluronan receptor) expression profile is 
similar to that of CD49c. To demonstrate the utility of employing such surface molecules 
to select high CC chondrocytes from mixed populations, cells were incubated with 
antibodies against CD49c or CD44 and sorted on the basis of the fluorescence intensity 
(low and high CD if respectively lower or higher than the mean value). (b) The cell 
population with brighter CD49c or CD44 signal produced tissues with greater GAG 
content and higher collagen type II at both the protein and gene expression level as 
compared to unsorted cells (c-d). Values are reported as mean ± standard error of the 
mean. * = statistically significant difference from unsorted chondrocytes. 
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CC        CC       CC        CC CC        CC        CC       CC         CC        CC CC 
DIFFERENTIALLY EXPRESSED GENES IN HIGH vs LOW CHONDROGENIC CAPACITY CELLS 
Accession number Gene Symbol Gene Title Fold Change q-value (%)
NM_000210 ITGA6 integrin, alpha 6 (CD49f) 4.76 5.5 
NM_013230 CD24 CD24 antigen  4.76 5.1 
NM_030820 COL21A1 collagen, type XXI, alpha 1 4.35 5.5 
NM_005501 ITGA3 integrin, alpha 3 (CD49c) 3.23 5.5 
NM_003238 TGFB2 transforming growth factor, beta 2 3.13 4.6 
NM_005978 S100A2 S100 calcium binding protein A2  3.13 5.5 
NM_001897 CSPG4 chondroitin sulfate proteoglycan 4  2.33 3.2 
NM_213569 NEBL nebulette 2.13 4.6 
NM_002998 SDC2 syndecan 2 (heparan sulfate proteoglycan 1) 1.96 2.7 
NM_002081 GPC1 glypican 1 1.85 5.5 
NM_005022 PFN1 Profiling 1 1.82 4.6 
NM_006888 CALM1 calmodulin 1 (phosphorylase kinase, delta) 1.67 5.1 
NM_001024212 S100A13 S100 calcium binding protein A13 1.59 0.0 
AA909121 ACTN1 actinin, alpha 1 1.45 0.0 
NM_014782 ARMCX2 armadillo repeat containing, X-linked 2 1.43 4.6 
NM_005864 EFS embryonal Fyn-associated substrate 1.35 5.6 
NM_014923 FNDC3A fibronectin type III domain containing 3 -1.40 5.4 
NM_004329 BMPR1A bone morphogenetic protein receptor, type IA -1.42 1.9 
NM_002414 CD99 CD99 antigen -1.53 5.1 
NM_014350 TNFAIP8 tumor necrosis factor, alpha-induced protein 8 -1.56 3.8 
NM_004530 MMP2 matrix metalloproteinase 2 (MMP2) -1.64 0.0 
NM_007038 ADAMTS5 aggrecanase-2  -1.67 5.4 
NM_000618 IGF1 insulin-like growth factor 1 (somatomedin C) -10.15 2.8 
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